📊 Dashboard
Active Drug Programs
24
Clinical Trials
18
Regulatory Submissions
7
Safety Reports
142
+12 this month
📈 Program Timelines (Critical Path)
Compound X (NME)
Biologic Y
Generic Z (ANDA)
🗂️ eCTD Module Status
| Module | Status | % Complete |
|---|---|---|
| Module 1 (Admin) | Approved | 100% |
| Module 2 (Summaries) | In Review | 85% |
| Module 3 (Quality) | Draft | 60% |
| Module 4 (Nonclinical) | Missing | 0% |
| Module 5 (Clinical) | Draft | 70% |
🔍 Recent Alerts
⚠️ Critical: Module 4 Quality dossier missing. EMA submission at risk.
⚡ Warning: 3 safety signals under evaluation (MedDRA review pending).
✓ Success: FDA Pre-submission meeting scheduled for Q2.
📋 eCTD v4.0 Backbone
🗂️ ▼ eCTD (Root)
Module 2 — Summaries
Quality Summary
2.0 QOS
Nonclinical Summary
2.1 NCS
Clinical Summary
2.2 COS
Module 2.0 — Quality Overall Summary (QOS)
Covers pharmaceutical development, substance characterization, drug product formulation & manufacturing, analytical methods, stability data, and container closure systems.
85% complete — 342 pages of 402
🏷️ Regional Labeling
USA — FDA Prescribing Information
| Section | FDA Requirement | Status |
|---|---|---|
| Highlights | Boxed Warning (if applicable), Recent changes, Highlights content | Complete |
| Indications & Usage | Specific, comprehensive indication text | Complete |
| Dosage & Administration | Dose, route, frequency, special populations | In Review |
| Contraindications | Absolute contraindications only | Draft |
🇺🇸 FDA Label
FDA PI (Prescribing Information) format. Includes Boxed Warnings, Clinical Pharmacology, and post-marketing experience.
🇪🇺 EMA SmPC
EMA Summary of Product Characteristics. Follows ICH CTD Module 1.3 format.
🇯🇵 PMDA RMP
PMDA Risk Management Plan & Japanese label requirements.
✍️ E-Signatures (21 CFR Part 11)
Signed Documents Registry
| Document | Signer | Role | Signature Date | Status |
|---|---|---|---|---|
| Protocol v2.1 (IND-001) | Dr. James Wilson | Principal Investigator | 2024-03-15 | Signed |
| RMP (Risk Management Plan) | Dr. Sarah Chen | Head of Safety | 2024-03-20 | Signed |
| Module 1 Certifications | Dr. Lisa Park | Regulatory Head | Pending | Awaiting Signature |
Signature Requirements
- Unique electronic signature (password + biometric optional)
- Audit trail of all access and modifications
- Timestamp synchronized with master clock
- Non-repudiation: signer cannot deny signing
- Meaning: signed = responsibility for content
Compliance Standards
FDA 21 CFR 11 — Electronic Records; Electronic Signatures
EU Annex 11 — Computerized Systems (GMP)
PMDA ASPN — Japanese e-signature framework
🔍 Signal Detection (MedDRA)
🚨 Hepatotoxicity Alert
MedDRA Code
10019684 (Hepatitis)
Reports
24
Severity
SERIOUS
Action
Under Review
⚠️ Renal Impairment
MedDRA Code
10038262 (Renal Disorder)
Reports
12
Severity
MODERATE
Action
Labeling Update
✓ Nausea (Expected)
MedDRA Code
10028813 (Nausea)
Reports
156
Severity
MILD
Action
Known AE
📊 Signal Analysis by Region
📈 Critical Path Analysis
Project: Compound X — Critical Path to FDA Approval
Protocol Finalization
IND Submission
Phase I Clinical Trial
Phase II Protocol Dev
Phase II Trial
Phase III Design & Start
Phase III Completion
NDA Assembly & Filing
📍 Estimated approval: Q3 2028 (58 months from now)
Current Phase
Phase I (In Progress)
Months to Approval
58
Risk Level
MODERATE
Budget Status
On Track
🔄 Parallel Submission Tracker
Submission Status by Region
| Region | Agency | Submission Type | Target Date | Status | Days to Deadline |
|---|---|---|---|---|---|
| 🇺🇸 United States | FDA CDER | NDA (New Drug Application) | Q4 2028 | Planning | 618 |
| 🇪🇺 European Union | EMA CHMP | MAA (Marketing Authorization Application) | Q1 2029 | Planning | 679 |
| 🇯🇵 Japan | PMDA | NDA (New Drug Application) | Q2 2029 | Planning | 740 |
| 🇬🇧 United Kingdom | MHRA | MAA | Q1 2029 | Planning | 679 |
📋 Regulatory Timeline
FDA approval (if granted) → 6-month gap → EMA submission → 12 months review → Approval
💼 Dossier Harmonization
All modules follow ICH CTD format. Regional variations documented in Module 1.3.
🎯 Key Deliverables
- eCTD conversion by Q3 2028
- RMP finalization by Q3 2028
- Regional labels by Q4 2028
🧪 Drug Specifications
Drug Specifications content would be displayed here.
✅ CTD Module Checklist
CTD Module Checklist content would be displayed here.
🔬 Clinical Trials
Clinical Trials content would be displayed here.
📊 Analytics & Diagnostics
Analytics & Diagnostics content would be displayed here.
🧫 Bioanalytical Validation
Bioanalytical Validation content would be displayed here.
🏥 Regulatory Submissions
Regulatory Submissions content would be displayed here.
📋 Regulatory Requirements
Regulatory Requirements content would be displayed here.
🏭 Manufacturing (cGMP)
Manufacturing (cGMP) content would be displayed here.
💊 Pharmacovigilance
Pharmacovigilance content would be displayed here.
🔒 Administration
Administration content would be displayed here.
💾 Evidence Lake
Evidence Lake content would be displayed here.
⚠️ Safety Signal Register
Safety Signal Register content would be displayed here.